Kaiser, Hannah
Wang, Xing
Kvist-Hansen, Amanda
Krakauer, Martin
Gørtz, Peter Michael
McCauley, Benjamin D.
Skov, Lone
Becker, Christine
Hansen, Peter Riis
Funding for this research was provided by:
LEO Fondet (LF16115)
Article History
Received: 6 June 2021
Accepted: 20 October 2021
First Online: 2 November 2021
Competing interests
: P.R.H. is recipient of a Borregaard Clinical Scientist Fellowship from the NOVO Nordisk Foundation and chairs a clinical academic group supported by the Greater Region of Copenhagen Health Science Partners. C.B. is a consultant for Onegevity Health. L.S. has been a paid speaker for Eli Lilly, AbbVie and LEO Pharma, and has been a consultant or served on Advisory Boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, Admirall and Sanofi. She has served as an investigator for AbbVie, Janssen Cilag, Boehringer Ingelheim, AstraZenica, Eli Lilly, Novartis, Regeneron and LEO Pharma, and has received research and educational grants from Pfizer, AbbVie, Novartis, Sanofi, Janssen Cilag and Leo Pharma. H.K., X.W., A.K-H., M.K., P.M.G and B.M have nothing to declare.